Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.
Teva and Natco Pharma have capitalized on the opportunity to introduce the first generic version of Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) in the US, bringing much-needed competition to the multiple myeloma market.
The Israeli firm has announced launch of generic lenalidomide capsules in four strengths: 5mg, 10mg, 15mg, and 25mg. Its Arrow subsidiary had won approval for its ANDA in May 2021, with the potential for 180 days of generic market exclusivity
Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
